Oncogene Journal

Overview

publication venue for

• Correction: Notch3-regulated microRNAs impair CXCR4-dependent maturation of thymocytes allowing maintenance and progression of T-ALL. 2024
• Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions. 2024
• Correction: Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance. 2023
• Genetic basis for iMCD-TAFRO. 2020
• Notch3-regulated microRNAs impair CXCR4-dependent maturation of thymocytes allowing maintenance and progression of T-ALL. 2024
• RNA-sequencing predicts a role of androgen receptor and aldehyde dehydrogenase 1A1 in osteosarcoma lung metastases..  43. 2024
• Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer. 2023
• IGF2BP1 regulates the cargo of extracellular vesicles and promotes neuroblastoma metastasis. 2023
• TrkA expression directs the anti-neoplastic activity of MLK3 inhibitors in triple-negative breast cancer..  42. 2023
• STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential. 2022
• FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A..  41. 2022
• Elevated expression of the colony-stimulating factor 1 (CSF1) induces prostatic intraepithelial neoplasia dependent of epithelial-Gp130. 2022
• Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer..  41. 2021
• MAP4K4 promotes pancreatic tumorigenesis via phosphorylation and activation of mixed lineage kinase 3. 2021
• POU1F1 transcription factor induces metabolic reprogramming and breast cancer progression via LDHA regulation..  40. 2021
• High levels of LINE-1 transposable elements expressed in Kaposi's sarcoma-associated herpesvirus-related primary effusion lymphoma..  40. 2020
• Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth..  39. 2020
• Lipogenic signalling modulates prostate cancer cell adhesion and migration via modification of Rho GTPases..  39. 2020
• Androgen receptor with short polyglutamine tract preferably enhances Wnt/β-catenin-mediated prostatic tumorigenesis..  39. 2020
• HIPK2 suppresses tumor growth and progression of hepatocellular carcinoma through promoting the degradation of HIF-1α..  39. 2020
• The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma..  39. 2019
• Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer..  38. 2019
• Regulation of neuroblastoma migration, invasion, and in vivo metastasis by genetic and pharmacological manipulation of MDA-9/Syntenin..  38. 2019
• HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells..  38. 2019
• Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate..  38. 2019
• Androgen signaling is essential for development of prostate cancer initiated from prostatic basal cells..  38. 2018
• Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity..  38. 2018
• Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer..  38. 2018
• The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor..  38. 2018
• Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer..  38. 2018
• Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma..  37. 2018
• Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer..  37. 2018
• Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma..  37. 2018
• PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence..  37. 2018
• KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function..  37. 2018
• Fibroblast-derived CXCL12 promotes breast cancer metastasis by facilitating tumor cell intravasation..  37. 2018
• Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis..  37. 2018
• CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer..  36. 2017
• Selected mitochondrial DNA landscapes activate the SIRT3 axis of the UPR^mt to promote metastasis..  36. 2017
• Upregulation of RET induces perineurial invasion of pancreatic adenocarcinoma..  36. 2017
• Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence..  36. 2016
• Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer..  36. 2016
• NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma..  36. 2016
• Myeloid translocation genes differentially regulate colorectal cancer programs..  35. 2016
• VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors..  36. 2016
• ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT..  35. 2015
• DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2..  34. 2015
• Cigarette smoke mediates epigenetic repression of miR-217 during esophageal adenocarcinogenesis..  34. 2015
• Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation..  34. 2015
• NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma..  34. 2015
• Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability..  34. 2014
• Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance..  34. 2014
• Thrombospondin-1 repression is mediated via distinct mechanisms in fibroblasts and epithelial cells..  34. 2014
• Nfkb1 is a haploinsufficient DNA damage-specific tumor suppressor..  34. 2014
• RECK controls breast cancer metastasis by modulating a convergent, STAT3-dependent neoangiogenic switch..  34. 2014
• Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer..  34. 2014
• High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma..  34. 2014
• A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis..  34. 2014
• The transcriptional modulator BCL6 as a molecular target for breast cancer therapy..  34. 2014
• Lysyl oxidase-like 2 (LOXL2) and E47 EMT factor: novel partners in E-cadherin repression and early metastasis colonization..  34. 2014
• Oncogenic Y641 mutations in EZH2 prevent Jak2/β-TrCP-mediated degradation..  34. 2014
• Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition..  33. 2013
• HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer..  33. 2013
• Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase..  33. 2013
• N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties..  33. 2013
• EZH2 promotes a bi-lineage identity in basal-like breast cancer cells..  32. 2013
• Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis..  33. 2013
• EphA2 promotes epithelial-mesenchymal transition through the Wnt/β-catenin pathway in gastric cancer cells..  33. 2013
• BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling..  33. 2013
• Engineering a single ubiquitin ligase for the selective degradation of all activated ErbB receptor tyrosine kinases..  33. 2013
• TRIM3, a tumor suppressor linked to regulation of p21(Waf1/Cip1.)..  33. 2013
• The Cul4A-DDB1 E3 ubiquitin ligase complex represses p73 transcriptional activity..  32. 2012
• Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery..  32. 2012
• RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination..  32. 2012
• p21CIP1 mediates reciprocal switching between proliferation and invasion during metastasis..  32. 2012
• The ubiquitin-specific protease USP2a prevents endocytosis-mediated EGFR degradation..  32. 2012
• Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression..  32. 2012
• A general method to derive robust organ-specific gene expression-based differentiation indices: application to thyroid cancer diagnostic..  31. 2012
• CHMP6 and VPS4A mediate the recycling of Ras to the plasma membrane to promote growth factor signaling..  31. 2012
• Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression..  31. 2011
• NPM-ALK signals through glycogen synthase kinase 3β to promote oncogenesis..  31. 2011
• Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions..  31. 2011
• A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis..  31. 2011
• Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production..  31. 2011
• Phosphorylation of RelA/p65 promotes DNMT-1 recruitment to chromatin and represses transcription of the tumor metastasis suppressor gene BRMS1..  31. 2011
• Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF..  31. 2011
• Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition..  30. 2011
• Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling..  30. 2011
• PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer..  30. 2011
• Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth..  30. 2010
• Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22..  30. 2010
• A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17..  30. 2010
• Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation..  29. 2010
• The NADPH oxidases NOX4 and DUOX2 regulate cell cycle entry via a p53-dependent pathway..  29. 2010
• Lipid raft-targeted therapy in multiple myeloma..  29. 2010
• Synergistic action of Smad4 and Pten in suppressing pancreatic ductal adenocarcinoma formation in mice..  29. 2009
• Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth..  29. 2009
• An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors..  28. 2009
• A critical role for choline kinase-alpha in the aggressiveness of bladder carcinomas..  28. 2009
• MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family..  28. 2009
• The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC..  28. 2008
• Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay..  28. 2008
• Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer..  27. 2008
• Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays..  27. 2008
• Loss of human Scribble cooperates with H-Ras to promote cell invasion through deregulation of MAPK signalling..  27. 2008
• Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis..  27. 2007
• Complex patterns of ETS gene alteration arise during cancer development in the human prostate..  27. 2007
• Distinct FAK-Src activation events promote alpha5beta1 and alpha4beta1 integrin-stimulated neuroblastoma cell motility..  27. 2007
• Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer..  27. 2007
• Prevalence and functional consequence of PHOX2B mutations in neuroblastoma..  27. 2007
• The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors..  27. 2007
• Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen..  26. 2007
• TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort..  26. 2007
• Tumor promoting properties of the ETS protein MEF in ovarian cancer..  26. 2007
• Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1..  26. 2006
• Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling..  26. 2006
• The tumour-suppressor Scribble dictates cell polarity during directed epithelial migration: regulation of Rho GTPase recruitment to the leading edge..  26. 2006
• UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas..  26. 2006
• Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation..  25. 2006
• Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways..  25. 2006
• Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase..  25. 2006
• ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression..  25. 2006
• BACH1 is a DNA repair protein supporting BRCA1 damage response..  25. 2006
• Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells..  25. 2006
• Subcellular localization and nucleocytoplasmic transport of the chromosomal passenger proteins before nuclear envelope breakdown..  25. 2006
• ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO..  25. 2006
• An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen..  25. 2006
• Gene expression-based classification of nonseminomatous male germ cell tumors..  24. 2005
• Accumulation of hypoxia-inducible factor-1alpha is limited by transcription-dependent depletion..  24. 2005
• Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice..  24. 2005
• The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression..  23. 2004
• Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2..  23. 2004
• Truncated mutants of the putative Wnt receptor LRP6/Arrow can stabilize beta-catenin independently of Frizzled proteins..  23. 2004
• Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)..  23. 2004
• Identification of NPM-ALK interacting proteins by tandem mass spectrometry..  23. 2004
• The KSHV G protein-coupled receptor signals via multiple pathways to induce transcription factor activation in primary effusion lymphoma cells..  23. 2004
• hScrib is a functional homologue of the Drosophila tumour suppressor Scribble..  22. 2003
• Acute expression of RET/PTC induces isozyme-specific activation and subsequent downregulation of PKCepsilon in PCCL3 thyroid cells..  22. 2003
• Ceramide-mediated clustering is required for CD95-DISC formation..  22. 2003
• RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase..  22. 2003
• Neurotrophin-induced melanoma cell migration is mediated through the actin-bundling protein fascin..  22. 2003
• Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors..  22. 2003
• IGF-1 activates p21 to inhibit UV-induced cell death..  22. 2003
• Bcl-x(L) and Akt cooperate to promote leukemogenesis in vivo..  22. 2003
• Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase..  22. 2003
• Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes..  22. 2003
• Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers..  21. 2002
• Localization of deletion to a 300 Kb interval of chromosome 11q13 in cervical cancer..  21. 2002
• Human rgr: transforming activity and alteration in T-cell malignancies..  21. 2002
• Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation..  21. 2002
• TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells..  21. 2002
• CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential..  21. 2002
• Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras..  21. 2002
• Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis..  21. 2002
• An endonuclease/ligase based mutation scanning method especially suited for analysis of neoplastic tissue..  21. 2002
• Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2..  21. 2002
• Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death..  21. 2002
• Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas..  20. 2001
• The de-ubiquitinating enzyme Unp interacts with the retinoblastoma protein..  20. 2001
• STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications..  20. 2001
• Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity..  20. 2001
• Mutations in the mitotic check point gene, MAD1L1, in human cancers..  20. 2001
• Loss of p53 tumor suppressor function is required for in vivo progression of Friend erythroleukemia..  20. 2001
• Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding..  20. 2001
• Cytokine response gene 8 (CR8) regulates the cell cycle G1-S phase transition and promotes cellular survival..  20. 2001
• Phosphorylation of the EWS IQ domain regulates transcriptional activity of the EWS/ATF1 and EWS/FLI1 fusion proteins..  20. 2001
• A novel mutation within the extracellular domain of TrkA causes constitutive receptor activation..  20. 2001
• The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25..  20. 2001
• A comparative evaluation of beta-catenin and plakoglobin signaling activity..  19. 2000
• Tumor-associated Apc mutations in Mlh1-/- Apc1638N mice reveal a mutational signature of Mlh1 deficiency..  19. 2000
• Interaction of the retinoblastoma protein (pRb) with the catalytic subunit of DNA polymerase delta (p125)..  19. 2000
• The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway..  19. 2000
• Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer..  19. 2000
• Initiation of translation from a downstream in-frame AUG codon on BRCA1 can generate the novel isoform protein DeltaBRCA1(17aa)..  19. 2000
• Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer..  19. 2000
• Cell line dependence of Bcl-2-induced alteration of glutathione handling..  19. 2000
• Cytokine response gene 6 induces p21 and regulates both cell growth and arrest..  18. 1999
• Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas..  18. 1999
• Characterization of S6K2, a novel kinase homologous to S6K1..  18. 1999
• CR6: A third member in the MyD118 and Gadd45 gene family which functions in negative growth control..  18. 1999
• The EWS/TEC fusion protein encoded by the t(9;22) chromosomal translocation in human chondrosarcomas is a highly potent transcriptional activator..  18. 1999
• Multiplex PCR/LDR for detection of K-ras mutations in primary colon tumors..  18. 1999
• MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas..  17. 1998
• Prevalence of minisatellite and microsatellite instability in radiation-induced post-Chernobyl pediatric thyroid carcinomas..  17. 1998
• The germinal center kinase (GCK)-related protein kinases HPK1 and KHS are candidates for highly selective signal transducers of Crk family adapter proteins..  17. 1998
• FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas..  17. 1998
• Hypomethylation and increased gene expression of p16INK4a in primary and metastatic breast carcinoma as compared to normal breast tissue..  16. 1998
• Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation..  16. 1998
• Development of highly selective SH3 binding peptides for Crk and CRKL which disrupt Crk-complexes with DOCK180, SoS and C3G..  16. 1998
• Functional role for the c-Abl tyrosine kinase in meiosis I..  16. 1998
• High frequency of simultaneous loss of p16 and p16beta gene expression in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus or stomach..  15. 1997
• Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas..  15. 1997
• Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer..  15. 1997
• Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases..  14. 1997
• The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera..  14. 1997
• A novel human SPS1/STE20 homologue, KHS, activates Jun N-terminal kinase..  14. 1997
• Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation..  14. 1997
• Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E down-regulation..  13. 1996
• Down-regulation of gadd153 by c-myc in rat fibroblasts and its effect on cell growth and radiation-induced apoptosis..  13. 1996
• Proline-rich sequences mediate the interaction of the Arg protein tyrosine kinase with Crk..  13. 1996
• Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident..  13. 1996
• Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia..  13. 1996
• Subcellular localization of the Arg protein tyrosine kinase..  13. 1996
• Deletion mapping identifies loss of heterozygosity at 5p15.1-15.2, 5q11 and 5q34-35 in human male germ cell tumors..  12. 1996
• Identification of ArgBP1, an Arg protein tyrosine kinase binding protein that is the human homologue of a CNS-specific Xenopus gene..  12. 1996
• Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells..  12. 1996
• Phosphorylation of c-Fos at the C-terminus enhances its transforming activity..  12. 1996
• Reduced and altered DNA-binding and transcriptional properties of the PLZF-retinoic acid receptor-alpha chimera generated in t(11;17)-associated acute promyelocytic leukemia..  12. 1996
• Overexpression of the Sky receptor tyrosine kinase at the cell surface or in the cytoplasm results in ligand-independent activation..  11. 1995
• Growth suppression of transformed human bronchial epithelial cells by all-trans-retinoic acid occurs through specific retinoid receptors..  11. 1995
• A mutated p53 gene alters thyroid cell differentiation..  11. 1995
• Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression..  11. 1995
• p53 dependent growth suppression by the c-Abl nuclear tyrosine kinase..  11. 1995
• Overexpression of the retinoic acid receptor gamma directly induces terminal differentiation of human embryonal carcinoma cells..  10. 1995
• Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer..  10. 1995
• Binding in vitro of phosphotyrosine-containing proteins to pp60c-src SH2 domain does not correlate with CEF transformation..  10. 1995
• Frequent allelic deletions and loss of expression characterize the DCC gene in male germ cell tumors..  9. 1994
• Allelic loss and somatic differentiation in human male germ cell tumors..  9. 1994
• A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line..  9. 1994
• Highly conserved amino acids in the SH2 and catalytic domains of v-src are altered in naturally occurring, transformation-defective alleles..  9. 1994
• Over-expression of transforming growth factor alpha antagonizes the anti-tumorigenic but not the differentiation actions of retinoic acid in a human teratocarcinoma cell..  8. 1993
• Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma..  8. 1993
• Regulation of trans-activating capacity of CRE-BPa by phorbol ester tumor promoter TPA..  8. 1993
• Synergistic increase of phorbol ester-induced c-fos mRNA expression by retinoic acid through stabilization of the c-fos message..  8. 1993
• Two wnt genes in Caenorhabditis elegans..  8. 1993
• Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype..  7. 1992
• The promoter of the human cystic fibrosis transmembrane conductance regulator gene directing SV40 T antigen expression induces malignant proliferation of ependymal cells in transgenic mice..  7. 1992
• Transformation of human kidney proximal tubule cells by a src-containing retrovirus..  6. 1991
• Differential expression of p62c-yes in normal, hyperplastic and neoplastic human epidermis..  6. 1991
• Detection of K-ras mutations in pancreatic and hepatic neoplasms by non-isotopic mismatched polymerase chain reaction..  6. 1991
• c-myc protein expression in untransformed fibroblasts..  6. 1991
• Molecular structure of double reciprocal translocations: significance in B-cell lymphomagenesis..  6. 1991
• Expression of transforming growth factor alpha in human gliomas..  5. 1990
• Expression of cellular-yes protein in mammalian tissues..  5. 1990
• Isochromosome 12p in non-seminoma cell lines: karyologic amplification of c-ki-ras2 without point-mutational activation..  5. 1990
• Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype..  4. 1989
• Molecular analysis of breaks in BCL-1 proto-oncogene in B-cell lymphomas with abnormalities of 11q13..  4. 1989
• Coordinate alteration of pp60c-src abundance and c-src RNA expression in human neuroblastoma variants..  4. 1989
• Normal development, oncogenesis and programmed cell death. 1998
• Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor..  40. 2021
• Role of diet in prostate cancer: the epigenetic link. 2014
• Genetic determinants at the interface of cancer and neurodegenerative disease. 2010
• The epithelial polarity program: machineries involved and their hijacking by cancer. 2008
• PTEN: a new guardian of the genome. 2008
• Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. 2007
• Mechanisms controlling pathogenesis and survival of leukemic stem cells. 2004
• Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. 2004
• Nedd8 on cullin: building an expressway to protein destruction. 2004
• Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. 2003
• Raft ceramide in molecular medicine. 2003
• Radiation and ceramide-induced apoptosis. 2003
• Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. 2003
• Clinical impact of novel treatment strategies. 2002
• The Id proteins and angiogenesis. 2001
• Transcriptional regulation in acute promyelocytic leukemia. 2001
• Translocations of the RARalpha gene in acute promyelocytic leukemia. 2001
• The role of the adapter molecule SLP-76 in platelet function. 2001
• The role of STATs in transcriptional control and their impact on cellular function. 2000
• Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. 2000
• Development of a flexible and specific gene delivery system for production of murine tumor models. 1999
• In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. 1999
• CXCR7 as a novel therapeutic target for advanced prostate cancer. 2023
• The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. 2000

Identity

ISO Abbreviation

• Oncogene

Linking ISSN

• 0950-9232

International Standard Serial Number (ISSN)

• 0950-9232

Electronic International Standard Serial Number (EISSN)

• 1476-5594